加载中

    The first case report of Enterococcus gallinarum meningitis in neonate: A literature review. Li Xiaoquan,Fan Shujuan,Lin Xiaojie,Liu Li,Zheng Jie,Zhou Xihui,Heep Axel Medicine RATIONALE:Enterococcus gallinarum meningitis (EGM) is rarely found in normal adults and even rarer in children. To our knowledge, EGM in neonate has not been reported previously. PATIENTS CONCERNS:Here we reported the first case of EGM in neonate. Prolonged fever was the only manifestation for the case after admission. DIAGNOSES:Cerebrospinal fluid cultures showed that the isolate was Enterococcus gallinarum and sensitive to linezolid. INTERVENTIONS:Ceftriaxone, beta lactam type, and vancomycin were used respectively, but not effective. OUTCOMES:The temperature went down to normal after linezolid was used and the baby was discharged in good condition in the end. LESSONS:This case indicated that EGM could also occur in neonate and fever could be the only obvious manifestation. Thus, the effective antibiotics and adequate duration are very important and linezolid is a potential good choice, especially for vancomycin-resistant patients. 10.1097/MD.0000000000009875
    Linezolid is Associated with Improved Early Outcomes of Childhood Tuberculous Meningitis. Li Huimin,Lu Jie,Liu Jinrong,Zhao Yuhong,Ni Xin,Zhao Shunying The Pediatric infectious disease journal BACKGROUND:Linezolid serves as an important component for the treatment of drug-resistant tuberculosis although there is little published data about linezolid use in children, especially in childhood tuberculous meningitis (TBM). METHODS:In this study, we retrospectively reviewed records of childhood TBM patients who started treatment between January 2012 and August 2014. A total of 86 childhood TBM patients younger than 15 years old were enrolled. Out of 86 children, 36 (41.9%) received the regimen containing linezolid. RESULTS:Thirty-two (88.9%) of 36 linezolid-treated cases had favorable outcomes, and 35 (70.0%) cases were successfully treated in the control group. The frequency of favorable outcome of linezolid group was significantly higher than that of control group (P = 0.037). In addition, compared with cases with fever clearance time of <1 week, the control group had more cases with fever clearance time of 1-4 weeks (P = 0.010) and >4 weeks (P = 0.000) than linezolid group. Furthermore, there was no significant difference in the frequency of adverse events between the two regimens (P = 0.896). In addition, the patients with adverse events were more likely to have treatment failure, the P value of which was 0.008. CONCLUSIONS:Our data demonstrate that linezolid improves early outcome of childhood TBM. The low frequency of linezolid-associated adverse effects highlights the promising prospects of its use for treatment of childhood TBM. 10.1097/INF.0000000000001114
    Therapeutic Effect of Linezolid in Children With Health Care-Associated Meningitis or Ventriculitis. Ochi Fumihiro,Tauchi Hisamichi,Nagai Kozo,Moritani Kyoko,Tezuka Mari,Jogamoto Toshihiro,Aibara Kaori,Motoki Takahiro,Ishii Eiichi Clinical pediatrics We evaluated the efficacy of linezolid treatment in 6 children with health care-associated meningitis or ventriculitis (HCAMV) caused by gram-positive cocci. All children were diagnosed and treated at the Ehime University Hospital between January 2010 and December 2017. Of these, 5 were treated with linezolid as an empirical therapy. In these 5 patients, vancomycin was initially used but was changed to linezolid because of cerebrospinal fluid (CSF) culture positivity (n = 3) and a high minimum inhibitory concentration of vancomycin (n = 2). The most common HCAMV pathogens were methicillin-resistant coagulase-negative staphylococci (n = 3). In 3 patients, vancomycin concentration was low in CSF but reached the target concentration in serum, while linezolid concentration was high in both CSF and serum. HCAMV treatment using antimicrobial agents with poor CSF penetration may increase the likelihood of therapy failure. Linezolid is more susceptible as the first-line treatment for HCAMV compared with vancomycin. 10.1177/0009922818803399